Percutaneous fiducial marker placement prior to stereotactic body radiotherapy for malignant liver tumors: an initial experience

• Published in: Journal of radiation research Vol. 57; no. 2; pp. 174 - 177
• Main Authors: Ohta, Kengo, Shimohira, Masashi, Murai, Taro, Nishimura, Junichi, Iwata, Hiromitsu, Ogino, Hiroyuki, Hashizume, Takuya, Shibamoto, Yuta
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.03.2016
• Subjects: Adult; Aged; Aged, 80 and over; Clinical Radiation Oncology; Female; Fiducial Markers - adverse effects; Humans; Liver Neoplasms - radiotherapy; Male; Middle Aged; Radiosurgery - adverse effects; Radiosurgery - methods; Skin; Treatment Outcome; fiducial marker; liver tumor; percutaneous; SBRT
• ISSN: 0449-3060; 1349-9157
• DOI: 10.1093/jrr/rrv099

The aim of this study was to describe our initial experience with a gold flexible linear fiducial marker and to evaluate the safety and technical and clinical efficacy of stereotactic body radiotherapy using this marker for malignant liver tumors. Between July 2012 and February 2015, 18 patients underwent percutaneous fiducial marker placement before stereotactic body radiotherapy for malignant liver tumors. We evaluated the technical and clinical success rates of the procedure and the associated complications. Technical success was defined as successful placement of the fiducial marker at the target site, and clinical success was defined as the completion of stereotactic body radiotherapy without the marker dropping out of position. All 18 fiducial markers were placed successfully, so the technical success rate was 100% (18/18). All 18 patients were able to undergo stereotactic body radiotherapy without marker migration. Thus, the clinical success rate was 100% (18/18). Slight pneumothorax occurred as a minor complication in one case. No major complications such as coil migration or bleeding were observed. The examined percutaneous fiducial marker was safely placed in the liver and appeared to be useful for stereotactic body radiotherapy for malignant liver tumors.